文献速递慢阻肺呼吸道感染

多西环素用于门诊治疗的慢阻肺急性加重:随机双盲安慰剂对照试验

Doxycycline for outpatient-treated acute exacerbations of COPD: a randomised double-blind placebo-controlled trial.
PubMed 文献 · Lancet Respir Med · 2017-05-05

不良事件和严重不良事件两组无显著差异。结果不支持门诊慢阻肺急性加重常规处方抗生素。

要点

  • 门诊慢阻肺急性加重在泼尼松龙基础上加多西环素未延长至下次加重时间。
  • 两组不良事件及严重不良事件发生率无显著差异。

核心结论

  • 在门诊接受治疗的轻至重度慢阻肺急性加重患者中,多西环素联合泼尼松龙与单用泼尼松龙相比未延长至下次急性加重的时间。

研究设计与样本

  • 随机双盲安慰剂对照试验,从荷兰9家教学医院和3家初级保健中心门诊招募887例慢阻肺患者队列。
  • 305例(34%)发生急性加重者随机分配至多西环素组(152例)或安慰剂组(153例),排除4例错误随机分配者后分析301例。
  • 多西环素方案为口服100 mg每日一次共7天(首日200 mg),两组均口服泼尼松龙30 mg每日一次共10天。

主要发现

  • 301例中257例(85%)出现下次急性加重,多西环素组131/150例(87%),安慰剂组126/151例(83%)。
  • 2年随访期间严重不良事件多西环素组42/150例(28%),安慰剂组43/151例(29%),p=1。

临床怎么用

  • 门诊慢阻肺急性加重在口服泼尼松龙基础上加用多西环素未显示延长至下次加重时间的获益,结果不支持门诊常规处方抗生素。

局限性

  • 研究纳入GOLD 1-3级、年龄≥45岁且有至少10包年吸烟史的患者,外推至其他人群需谨慎。
  • 随机化排除发热、需住院或近3周内使用抗生素的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antibiotics do not reduce mortality or short-term treatment non-response in patients receiving treatment for acute exacerbations of COPD in an outpatient setting. However, the long-term effects of antibiotics are unknown. The aim of this study was to investigate if the antibiotic doxycycline added to the oral corticosteroid prednisolone prolongs time to next exacerbation in patients with COPD receiving treatment for an exacerbation in the outpatient setting. METHODS: In this randomised double-blind placebo-controlled trial, we recruited a cohort of patients with COPD from outpatient clinics of nine teaching hospitals and three primary care centres in the Netherlands. Inclusion criteria were an age of at least 45 years, a smoking history of at least 10 pack-years, mild-to-severe COPD (Global Initiative of Chronic Obstructive Lung Disease [GOLD] stage 1-3), and at least one exacerbation during the past 3 years. Exclusion criteria were poor mastery of the Dutch language, poor cognitive functioning, known allergy to doxycycline, pregnancy, and a life expectancy of shorter than 1 month. If a participant had an exacerbation, we randomly assigned them (1:1; with permuted blocks of variable sizes [ranging from two to ten]; stratified by GOLD stage 1-2 vs 3) to a 7 day course of oral doxycycline 100 mg daily (200 mg on the first day) or placebo. Exclusion criteria for randomisation were fever, admission to hospital, and current use of antibiotics or use within the previous 3 weeks. Patients in both groups received a 10 day course of 30 mg oral prednisolone daily. Patients, investigators, and those assessing outcomes were masked to treatment assignment. The primary outcome was time to next exacerbation in all randomly allocated patients except for those incorrectly randomly allocated who did not meet the inclusion criteria or met the exclusion criteria. This trial is registered with the Netherlands Trial Register, number NTR2499. FINDINGS: Between Dec 22, 2010, and Aug 6, 2013, we randomly allocated 305 (34%) patients from the cohort of 887 patients to doxycycline (152 [50%]) or placebo (153 [50%]), excluding four (1%) patients (two [1%] from each group) who were incorrectly randomly allocated from the analysis. 257 (85%) of 301 patients had a next exacerbation (131 [87%] of 150 in the doxycycline group vs 126 [83%] of 151 in the placebo group). Median time to next exacerbation was 148 days (95% CI 95-200) in the doxycycline group compared with 161 days (118-211) in the placebo group (hazard ratio 1·01 [95% CI 0·79-1·31]; p=0·91). We did not note any significant differences between groups in the frequency of adverse events during the first 2 weeks after randomisation (47 [31%] of 150 in the doxycycline group vs 53 [35%] of 151 in the placebo group; p=0·54) or in serious adverse events during the 2 years of follow-up (42 [28%] vs 43 [29%]; p=1). INTERPRETATION: In patients with mild-to-severe COPD receiving treatment for an exacerbation in an outpatient setting, the antibiotic doxycycline added to the oral corticosteroid prednisolone did not prolong time to next exacerbation compared with prednisolone alone. These findings do not support prescription of antibiotics for COPD exacerbations in an outpatient setting. FUNDING: Netherlands Organization for Health Research and Development.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. van Velzen P, Ter Riet G, Bresser P, et al. Doxycycline for outpatient-treated acute exacerbations of COPD: a randomised double-blind placebo-controlled trial. Lancet Respir Med. 2017. PMID: 28483402. doi:10.1016/S2213-2600(17)30165-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。